John M Barnwell

US Patent:

6706872, Mar 16, 2004

Filed:

Sep 30, 1996

Appl. No.:

08/719821

Inventors:

John W. Barnwell - New York NY

Assignee:

New York University - New York NY

International Classification:

C07H 2104

US Classification:

536 237

Abstract:

This invention is directed to polynuclectides encoding novel species-specific malarial peptide antigens which are proteins or fragments of proteins secreted into the plasma of a susceptible mammalian host after infection, and to monoclonal or polyclonal antibodies directed against those antigens. The peptide antigens, monoclonal antibodies, and/or polyclonal antibodies are utilized in assays used to diagnose malaria, as well as to determine whether is the species responsible for the infection.

US Patent:

6958235, Oct 25, 2005

Filed:

Feb 14, 1997

Appl. No.:

09/125031

Inventors:

Shirley Longacre-Andre - Paris, FR
Charles Roth - Rueil-Malmaison, FR
Faridabano Nato - Antony, FR
John W. Barnwell - New York NY, US
Kamini Mendis - Columbo, LK

Assignee:

Institute Pasteur - Paris
New York University - New York NY

International Classification:

A61K039/015
C07H021/04
C12N015/30
C12P021/04

US Classification:

4353201, 4241911, 4242721, 435 693, 435 697, 435 698, 435 711, 4352351, 435348, 536 231, 536 234, 536 235, 536 237, 536 241

Abstract:

The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the type, particularly which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.

US Patent:

20070141075, Jun 21, 2007

Filed:

Jul 22, 2005

Appl. No.:

11/187736

Inventors:

John Barnwell - New York NY, US

Assignee:

New York University - New York NY

International Classification:

A61K 39/002
C07K 14/445

US Classification:

424191100, 530350000, 530388100

Abstract:

This invention is directed to novel species-specific malarial peptide antigens which are proteins or fragments of proteins secreted into the plasma of a susceptible mammalian host after infection, and to monoclonal or polyclonal antibodies directed against those antigens. The peptide antigens, monoclonal antibodies, and/or polyclonal antibodies are utilized in assays used to diagnose malaria, as well as to determine whether is the species responsible for the infection.

US Patent:

58745270, Feb 23, 1999

Filed:

Sep 30, 1996

Appl. No.:

8/719822

Inventors:

John W. Barnwell - New York NY

Assignee:

New York University - New York NY

International Classification:

A61K 3800
A61K 39015

US Classification:

530300

Abstract:

This invention is directed to novel species-specific P. vivax malarial peptide antigens which are proteins or fragments of proteins secreted into the plasma of a susceptible mammalian host after infection, and to monoclonal or polyclonal antibodies directed against those antigens. The peptide antigens, monoclonal antibodies, and/or polyclonal antibodies are utilized in assays used to diagnose malaria, as well as to determine whether Plasmodium vivax is the species responsible for the infection.

US Patent:

55321330, Jul 2, 1996

Filed:

Jun 2, 1993

Appl. No.:

8/072610

Inventors:

John W. Barnwell - New York NY

Assignee:

New York University - New York NY

International Classification:

G01N 3353
G01N 33543
G01N 33569
C07K 1620

US Classification:

435 722

Abstract:

This invention is directed to novel species-specific P. vivax malarial peptide antigens, PvESP-1 is a protein or fragments of the protein secreted into the plasma of a susceptible mammalian host after infection, and to monoclonal or polyclonal antibodies directed against this antigen. The peptide antigen, monoclonal antibodies, and/or polyclonal antibodies are utilized in assays used to diagnose malaria, as well as to determine whether Plasmodium vivax is the species responsible for the infection.

US Patent:

62318616, May 15, 2001

Filed:

Jun 5, 1998

Appl. No.:

9/092458

Inventors:

John W. Barnwell - New York NY

Assignee:

New York University - New York NY

International Classification:

A61K 3900
C07K 100

US Classification:

4241841

Abstract:

This invention is directed to novel species-specific P. vivax malarial peptide antigens which are proteins or fragments of proteins secreted into the plasma of a susceptible mammalian host after infection, and to monoclonal or polyclonal antibodies directed against those antigens. The peptide antigens, monoclonal antibodies, and/or polyclonal antibodies are utilized in assays used to diagnose malaria, as well as to determine whether Plasmodium vivax is the species responsible for the infection.

US Patent:

56462476, Jul 8, 1997

Filed:

Oct 4, 1991

Appl. No.:

7/792865

Inventors:

John W. Barnwell - New York NY
Mary R. Galinski - New York NY

Assignee:

New York University - New York NY

International Classification:

C07K 1444
C12N 1530
A61K 39005
A61K 3900

US Classification:

530350

Abstract:

Disclosed are compounds comprising an amino acid sequence selected from the group consisting of malarial merozoite proteins located at the apical end of merozoites and peptides the peptides comprising synthetic versions, derivatives, analogs and fragments of the merozoite proteins. Certain of these compounds have the property of binding to a Duffy blood group antigen from primate red blood cells. Disclosed are also nucleic acids comprising a nucleotide sequence encoding such peptides or proteins and nucleic acids hybridizing therewith. The compounds and antibodies recognizing these compounds are useful in inhibiting invasion of susceptible primate red blood cells by malarial merozoites.